IDX Share Price Performance
AU$2.61
-0.47 (-15.26%)
22.4% undervalued intrinsic discount
AU$3.36
Fair Value
Price AU$2.61
AnalystConsensusTarget AU$3.36
Fair ValueAU$3.36
Share PriceAU$2.61
22.4% undervalued intrinsic discount
Integral Diagnostics Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
IDX Community Narratives
AN
Fair Value AU$3.36 22.4% undervalued intrinsic discount
MRI Licensing And Lung Screening Will Expand Imaging Potential
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
MRI Licensing And Lung Screening Will Expand Imaging Potential
Key Takeaways Increased MRI capacity, strong merger integration, and new screening programs are driving sustained revenue growth and expanding margins for the core imaging business. Scaling teleradiology, use of AI, and easing labor constraints position the company to mitigate clinician shortages and boost future profitability.
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
AU$3.36
22.4% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
12.85% p.a.
Profit Margin
7.55%
Future PE
22.31x
Share price in 2028
AU$4.06
Snowflake Analysis
Integral Diagnostics Limited Key Details
About IDX
- Founded
- 1967
- Employees
- 3025
- CEO
- WebsiteView website
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. The company offers magnetic resonance imaging, positron emission tomography, computed tomography mammography, interventional radiology, ultrasound, and radiography, such as x-ray and EOS. Integral Diagnostics Limited was founded in 1967 and is headquartered in Melbourne, Australia.
